CRC patients with POLE mutation were reported to have positive treatment responses with immune checkpoint inhibitors (22), partly because of the high CD4+ T cell infiltrations and increased expressions of pro-inflammatory cytokines in the tumor microenvironment (23). This evidence concerns the gene POLE and colorectal carcinoma.